How Often Did Constipation Occur in the Retatrutide Phase 2 Trial?

Compare registered constipation counts across the seven phase 2 groups and see why the results do not establish a universal dose-by-dose pattern.

Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.

What safety observations can establish

The phase 2 obesity publication reported gastrointestinal adverse events, principally nausea, diarrhea, vomiting and constipation. Events were dose-related and mostly mild to moderate in that study, and increases in heart rate were also observed. These findings must be read alongside the study population, follow-up and discontinuations. They are not proof of long-term safety.

A symptom reported during a trial is not automatically caused by the investigational drug. Conversely, a trial that does not detect a rare event cannot exclude that risk. Safety estimates depend on how events were collected, the number of participants, comparator rates and duration of observation.

The cited research does not establish a personalized prediction, a proven symptom timeline or a home management protocol for the concern in this article. Physician supervision does not turn an investigational substance into an FDA-approved treatment. Participants should report adverse events to their study team rather than infer a dosing change from an article.

Constipation affected 10 of 62 participants in the 12 mg target group, compared with 2 of 70 in the placebo group, in the registered phase 2 obesity results. Calculated percentages are 16.1% and 2.9%. Across the retatrutide groups, the proportions ranged from 6.1% to 16.1%; they did not increase uniformly from one listed group to the next.

Constipation counts by phase 2 trial group

Registered group	Participants affected / at risk	Calculated percentage	Reported events
Placebo	2 / 70	2.9%	3
1 mg target	5 / 69	7.2%	7
4 mg target, 2 mg start	5 / 33	15.2%	6
4 mg target, 4 mg start	2 / 33	6.1%	3
8 mg target, 2 mg start	4 / 35	11.4%	5
8 mg target, 4 mg start	4 / 35	11.4%	4
12 mg target, 2 mg start	10 / 62	16.1%	13

The group results do not form a simple dose ladder

The 4 mg target group starting at 2 mg had 5 of 33 participants with constipation, or 15.2%. The 4 mg group starting at 4 mg had 2 of 33, or 6.1%. Both 8 mg groups had 4 of 35, or 11.4%, despite their different starting doses. The highest target group had 10 of 62, or 16.1%. These small-group observations do not support a rule that each dose increase adds a fixed constipation risk.

Repeated events and affected participants are different

The 12 mg group recorded 13 constipation events among 10 affected participants. The affected-participant proportion is 10/62, or 16.1%. Dividing 13 events by 62 would give 21.0%, which is not the percentage of participants who experienced constipation. This distinction matters when an online table presents an event total as a patient rate.

Does the trial show a typical onset or duration?

The aggregate adverse-event table does not establish when constipation usually begins, how many days an episode lasts or whether an individual's symptoms recur at a particular dose step. It also does not evaluate a specific diet, laxative or hydration intervention for constipation. Those questions require different data from the affected-person counts shown here.

How this comparison was calculated

The source is the posted results for NCT04881760, an obesity study of LY3437943, the development name for retatrutide. For each group, the percentage above equals participants affected divided by participants at risk, multiplied by 100 and rounded to one decimal place. The adverse-event follow-up runs from baseline through the end of safety follow-up, up to 52 weeks; the study's treatment and weight-loss reporting periods should not be substituted for that collection window.

The results report non-serious adverse-event terms meeting a frequency threshold of at least 5% in any treatment group. A term absent from that table is not automatically an event with zero occurrence. The table describes collected reports rather than establishing that every event was caused by treatment. These are phase 2 group results, not a pooled estimate combining phase 2 and later phase 3 studies.